- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06188689
Evaluering af en klinisk diagnostisk test for CRDS (DIAGNOSE CRDS)
Evaluering af en klinisk diagnostisk test for Calcium Release Deficiency Syndrome: DIAGNOSE CRDS-undersøgelsen
Calcium Release Deficiency Syndrome (CRDS) is a novel inherited arrhythmia syndrome secondary to RyR2 loss-of-function that confers a risk of sudden cardiac death. Diagnosis of CRDS presently requires cellular-based in vitro confirmation that an RyR2 variant causes loss-of-function. We hypothesize that CRDS can be diagnosed clinically through evaluation of the repolarization response to brief tachycardia, mediated by cardiac pacing, and a subsequent pause.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
RyR2 loss-of-function variants have recently been established as causative for a new disease termed calcium release deficiency syndrome (CRDS) that confers a risk of malignant ventricular arrhythmias and sudden cardiac death. RyR2 encodes the cardiac ryanodine receptor, the calcium release channel on the sarcoplasmic reticulum that mediates excitation-contraction coupling through calcium-induced calcium-release. In contrast to CRDS, pathogenic RyR2 gain-of-function variants result in an autosomal dominant form of catecholaminergic polymorphic ventricular tachycardia (CPVT). The adrenergic-mediated ventricular arrhythmias characteristic of CPVT can be readily reproduced on exercise stress testing (EST), making EST the standard clinical diagnostic tool for CPVT.
In contrast to CPVT, the CRDS clinical phenotype is concealed with standard cardiac testing tools and its diagnosis presently requires cellular-based in vitro confirmation that an RyR2 variant causes loss-of-function. Beyond the significant time delay associated with in vitro functional analysis, this testing requires specialized expertise that is not widely available and remains research-based, making it impractical for routine use in clinical care. In this overall context, it is likely that the vast majority of global CRDS cases have yet to be diagnosed.
A prior report of an "atypical CPVT" family carrying an RyR2-p.M4109R variant observed marked and transient repolarization changes following pacing mediated tachycardia and a subsequent pause. Since publication of this report, in vitro characterization of the RyR2-p.M4109R variant has confirmed its being loss-of-function and the familial diagnosis has been revised to CRDS. Driven by these observations and promising preliminary findings, the DIAGNOSE CRDS study seeks to further investigate this apparent electrocardiographic signature of CRDS following brief tachycardia and subsequent pause as a potential method to clinically diagnose the condition.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Jason Roberts, MD MAS
- Telefonnummer: 40632 905-297-3479
- E-mail: jason.roberts@phri.ca
Studiesteder
-
-
-
Brussels, Belgien, 1090
- Rekruttering
- Universitair Ziekenhuis Brussel
-
Kontakt:
- Project Manager
- Telefonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Ledende efterforsker:
- Luigi Pannone, MD
-
-
Antwerp
-
Edegem, Antwerp, Belgien, 2650
- Rekruttering
- Antwerp University Hospital
-
Ledende efterforsker:
- Johan Saenen, MD, PhD
-
Kontakt:
- Project Manager
- Telefonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 1N4
- Rekruttering
- University of Calgary
-
Ledende efterforsker:
- Erkan Ilhan, MD
-
Kontakt:
- Project Manager
- Telefonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Edmonton, Alberta, Canada, T6G 2C8
- Rekruttering
- Alberta Health Services
-
Kontakt:
- Project Manager
- Telefonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Ledende efterforsker:
- Joseph Atallah, MD CM, MSc
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6T 1Z3
- Rekruttering
- The University of British Columbia
-
Kontakt:
- Project Manager
- Telefonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Ledende efterforsker:
- Thomas M Roston, MD
-
Vancouver, British Columbia, Canada, V6H 3N1
- Rekruttering
- Children's & Women's Health Centre of British Columbia
-
Kontakt:
- Project Manager
- Telefonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Ledende efterforsker:
- Shubhayan Sanatani, MD
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 2X2
- Rekruttering
- Hamilton General Hospital
-
Ledende efterforsker:
- Jason D Roberts, MD MAS
-
Kontakt:
- Project Manager
- Telefonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
London, Ontario, Canada, N6A 5A5
- Rekruttering
- London Health Sciences Centre - University Hospital
-
Ledende efterforsker:
- Habib R Khan, MD
-
Kontakt:
- Project Manager
- Telefonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Ottawa, Ontario, Canada, K1Y 4W7
- Rekruttering
- Ottawa Heart Institute
-
Ledende efterforsker:
- Simon Hansom, MD
-
Kontakt:
- Project Manager
- Telefonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Toronto, Ontario, Canada, M5G 2C4
- Rekruttering
- Toronto General Hospital
-
Kontakt:
- Project Manager
- Telefonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Ledende efterforsker:
- Michael H. Gollob, MD, FRCP(C)
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 1C8
- Rekruttering
- Montréal Heart Institute
-
Ledende efterforsker:
- Rafik Tadros, MD PhD
-
Kontakt:
- Project Manager
- Telefonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Québec, Quebec, Canada, G1V 4G5
- Rekruttering
- Institut Universitaire de Cardiologie et de Pneumologie de Québec-Université Laval
-
Ledende efterforsker:
- Christian Steinberg, MD
-
Kontakt:
- Project Manager
- Telefonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
-
-
-
-
Aarhus, Danmark, DK-8200 N
- Rekruttering
- Aarhus University Hospital
-
Kontakt:
- Project Manager
- Telefonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Ledende efterforsker:
- Henrik Jensen, MD
-
-
-
-
London
-
London, London, Det Forenede Kongerige, WC1N 3JH
- Rekruttering
- Great Ormond Street Hospital
-
Kontakt:
- Project Manager
- Telefonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Ledende efterforsker:
- Luke Starling, BSc (Hons), MB BS, FRCPCH
-
-
Oxfordshire
-
Oxford, Oxfordshire, Det Forenede Kongerige, OX3 9DU
- Rekruttering
- Oxford University Hospitals
-
Kontakt:
- Project Manager
- Telefonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Ledende efterforsker:
- Julian Ormerod, BM, Bch, FRCP
-
-
-
-
California
-
San Francisco, California, Forenede Stater, 94143
- Rekruttering
- University of California
-
Kontakt:
- Project Manager
- Telefonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Ledende efterforsker:
- Vasanth Vedantham, MD, PhD
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02115
- Rekruttering
- Boston Children's Hospital
-
Kontakt:
- Project Manager
- Telefonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Ledende efterforsker:
- Dominic Abrams, MBBS, MD, MBA
-
-
Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905
- Rekruttering
- Mayo Clinic
-
Kontakt:
- Project Manager
- Telefonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Ledende efterforsker:
- John Giudicessi, MD, PhD
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98195
- Rekruttering
- University of Washington
-
Kontakt:
- Project Manager
- Telefonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Ledende efterforsker:
- Uyanga Batnyam, MD
-
-
-
-
New Aquitaine
-
Bordeaux, New Aquitaine, Frankrig, 33404
- Rekruttering
- CHU de Bordeaux
-
Kontakt:
- Project Manager
- Telefonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Ledende efterforsker:
- Frédéric Sacher, MD
-
-
-
-
-
Jerusalem, Israel, 9103102
- Rekruttering
- Shaare Zedek Medical Center
-
Kontakt:
- Project Manager
- Telefonnummer: 905-521-2100
- E-mail: crds@phri.ca
-
Ledende efterforsker:
- Ziv Dadon, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Cohort 1: Calcium Release Deficiency Syndrome (CRDS) Cases
Inclusion criteria:
• Presence of an RyR2 variant confirmed to be loss-of-function on in vitro testing
Exclusion criteria:
• Unable to provide informed consent
Cohort 2: Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Cases
Inclusion criteria:
- Satisfy a clinical phenotype consistent with the Expert Consensus Statement
- Presence of a confirmed or presumed pathogenic gain-of-function RyR2 variant OR homozygous or compound heterozygous for likely pathogenic/pathogenic CASQ2 variants
Exclusion criteria:
- Unable to provide informed consent
- Use of a QT prolonging medication, aside from flecainide, at the time of the burst pacing maneuvers
Cohort 3: Survivors of Unexplained Cardiac Arrest (UCA)
Inclusion criteria:
- Cardiac arrest requiring cardioversion or defibrillation that remains unexplained following an ECG, echocardiogram, coronary assessment, cardiac MRI, and exercise treadmill test
- Undergone genetic testing that includes screening of RyR2*
Exclusion criteria:
-
Unable to provide informed consent
-
Use of a QT prolonging medication at the time of the burst pacing maneuvers
- Among survivors of UCA that possess a rare RyR2 variant in the absence of a CPVT phenotype, in vitro functional testing will be performed in order to confirm it is not loss- or gain-of-function (and will be arranged through the laboratory of Dr. Wayne Chen at the University of Calgary).
Cohort 4: SVT controls
Inclusion criteria:
• Undergoing an invasive electrophysiology study
Exclusion criteria:
- Ventricular cardiomyopathy
- Ventricular pre-excitation
- Long QT syndrome
- Use of a QT prolonging medication at the time of the EP study
- Use of a Class I or Class III anti-arrhythmic drug at the time of the EP study
- Known obstructive coronary artery disease (existing coronary stenosis >50%)
- Unable to provide informed consent
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Diagnostisk
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Pacing
Separate ventricular and atrial pacing trains will be administered at different cycle lengths and the ventricular repolarization response on the first sinus beat following the subsequent pause will be evaluated. |
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
ΔT-wave amplitude value
Tidsramme: At time of pacing maneuver
|
T-wave amplitude on first post-pause sinus beat subtracted by the T-wave amplitude on the last sinus beat prior to pacing |
At time of pacing maneuver
|
|
ΔQT value
Tidsramme: At time of pacing maneuver
|
Absolute QT value on first post-pause sinus beat subtracted by the absolute QT value on the last sinus beat prior to pacing |
At time of pacing maneuver
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Absolute QT value
Tidsramme: At time of pacing maneuver
|
Absolute QT value on first post-pause sinus beat |
At time of pacing maneuver
|
|
Absolute T-wave amplitude
Tidsramme: At time of pacing maneuver
|
Absolute T-wave amplitude on first post-pause sinus beat |
At time of pacing maneuver
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Studieleder: Ziv Dadon, MD, Shaare Zedek Medical Center
- Ledende efterforsker: Jason D Roberts, MD MAS, McMaster University
- Ledende efterforsker: Wayne Chen, PhD, University of Calgary
Publikationer og nyttige links
Generelle publikationer
- Sun B, Yao J, Ni M, Wei J, Zhong X, Guo W, Zhang L, Wang R, Belke D, Chen YX, Lieve KVV, Broendberg AK, Roston TM, Blankoff I, Kammeraad JA, von Alvensleben JC, Lazarte J, Vallmitjana A, Bohne LJ, Rose RA, Benitez R, Hove-Madsen L, Napolitano C, Hegele RA, Fill M, Sanatani S, Wilde AAM, Roberts JD, Priori SG, Jensen HK, Chen SRW. Cardiac ryanodine receptor calcium release deficiency syndrome. Sci Transl Med. 2021 Feb 3;13(579):eaba7287. doi: 10.1126/scitranslmed.aba7287.
- Nof E, Belhassen B, Arad M, Bhuiyan ZA, Antzelevitch C, Rosso R, Fogelman R, Luria D, El-Ani D, Mannens MM, Viskin S, Eldar M, Wilde AA, Glikson M. Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene. Heart Rhythm. 2011 Oct;8(10):1546-52. doi: 10.1016/j.hrthm.2011.05.016. Epub 2011 May 26.
- Ormerod JOM, Ormondroyd E, Li Y, Taylor J, Wei J, Guo W, Wang R, Sarton CNS, McGuire K, Dreau HMP, Taylor JC, Ginks MR, Rajappan K, Chen SRW, Watkins H. Provocation Testing and Therapeutic Response in a Newly Described Channelopathy: RyR2 Calcium Release Deficiency Syndrome. Circ Genom Precis Med. 2022 Feb;15(1):e003589. doi: 10.1161/CIRCGEN.121.003589. Epub 2021 Dec 24.
- Roston TM, Wei J, Guo W, Li Y, Zhong X, Wang R, Estillore JP, Peltenburg PJ, Noguer FRI, Till J, Eckhardt LL, Orland KM, Hamilton R, LaPage MJ, Krahn AD, Tadros R, Vinocur JM, Kallas D, Franciosi S, Roberts JD, Wilde AAM, Jensen HK, Sanatani S, Chen SRW. Clinical and Functional Characterization of Ryanodine Receptor 2 Variants Implicated in Calcium-Release Deficiency Syndrome. JAMA Cardiol. 2022 Jan 1;7(1):84-92. doi: 10.1001/jamacardio.2021.4458.
- Ni M, Dadon Z, Ormerod JOM, Saenen J, Hoeksema WF, Antiperovitch P, Tadros R, Christiansen MK, Steinberg C, Arnaud M, Tian S, Sun B, Estillore JP, Wang R, Khan HR, Roston TM, Mazzanti A, Giudicessi JR, Siontis KC, Alak A, Acosta JG, Divakara Menon SM, Tan NS, van der Werf C, Nazer B, Vivekanantham H, Pandya T, Cunningham J, Gula LJ, Wong JA, Amit G, Scheinman MM, Krahn AD, Ackerman MJ, Priori SG, Gollob MH, Healey JS, Sacher F, Nof E, Glikson M, Wilde AAM, Watkins H, Jensen HK, Postema PG, Belhassen B, Chen SRW, Roberts JD. A Clinical Diagnostic Test for Calcium Release Deficiency Syndrome. JAMA. 2024 Jul 16;332(3):204-213. doi: 10.1001/jama.2024.8599.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 14546
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .